[{"from": "human", "value": "Describe this molecule. [C][N][C][=N][C][=C][Ring1][Branch1][C][=C][Branch2][Ring1][#Branch1][C][=Branch1][Branch1][=C][Ring1][=Branch1][F][N][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Br][F][C][=Branch1][C][=O][N][O][C][C][O]"}, {"from": "gpt", "value": "The molecule is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].  On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test."}]